Literature DB >> 8352849

Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group.

S T Iannaccone1, R H Browne, F J Samaha, C R Buncher.   

Abstract

Spinal muscular atrophy (SMA) is a common neuromuscular disorder of childhood, associated with a high mortality rate during the first 2 years of life. Most practitioners expect patients with SMA to follow a progressive course with loss of muscle strength and function over 2-10 years. Counselling sessions with parents frequently emphasize the high mortality rate and risk for respiratory failure. The progressive nature of SMA has been attributed to the loss of motor neurons. Fifty-eight children, ages 6 years and younger, were examined between January, 1987, and April, 1992, as part of a large, multicenter collaborative study of SMA. Muscle function was evaluated at regular intervals using a standardized protocol that was demonstrated to be reliable. We determined a prevalence of 56% for tongue fasciculations, a prevalence of 22% for facial weakness, and persistent deep tendon reflexes in one patient. Improved motor function and acquired milestones during the study were documented. This work should contribute toward a better understanding of the natural history of SMA.

Entities:  

Mesh:

Year:  1993        PMID: 8352849     DOI: 10.1016/0887-8994(93)90082-n

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  16 in total

1.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

2.  Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy.

Authors:  George Z Mentis; Dvir Blivis; Wenfang Liu; Estelle Drobac; Melissa E Crowder; Lingling Kong; Francisco J Alvarez; Charlotte J Sumner; Michael J O'Donovan
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 3.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 4.  Prevention and management of limb contractures in neuromuscular diseases.

Authors:  Andrew J Skalsky; Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

5.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

6.  Proximal Limb Girdle Weakness, Joint Hyperlaxity, and preserved Deep Tendon Reflexes: A Distinctive Phenotype.

Authors:  Priyanka Madaan; Lokesh Saini
Journal:  Indian Pediatr       Date:  2020-10-15       Impact factor: 1.411

Review 7.  The Genetics of Spinal Muscular Atrophy: Progress and Challenges.

Authors:  Michelle A Farrar; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

8.  Prospective study of gross motor development in children with SMA type II.

Authors:  R Bono; M Inverno; G Botteon; E Iotti; M Estienne; A Berardinelli; G Lanzi; E Fedrizzi
Journal:  Ital J Neurol Sci       Date:  1995-05

9.  Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response.

Authors:  Haiyan Zhou; Jinhong Meng; Elena Marrosu; Narinder Janghra; Jennifer Morgan; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2015-08-11       Impact factor: 5.121

10.  Drug treatment for spinal muscular atrophy type I.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.